Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26111048 | 0.90 | NMT2 (0.37) | MAPTSIRT5NMT2NMT1 | |
| SCHEMBL26111054 | 0.90 | NMT2 (0.37) | MAPTSIRT5NMT2NMT1 | |
| SCHEMBL28872431 | 0.86 | NMT2 (0.34) | MAPTHDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL26528590 | 0.86 | TDP1 (0.40) | MAPTTDP1GAAPAX8NPSR1 | |
| SCHEMBL26109645 | 0.84 | NMT2 (0.35) | MAPTHDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL26109642 | 0.84 | NMT2 (0.35) | MAPTHDAC4HDAC1HDAC3HDAC7 | |
| SCHEMBL25363954 | 0.81 | SIRT1 (0.34) | SIRT5NMT2NMT1 | |
| SCHEMBL24642859 | 0.80 | TDP1 (0.36) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL24642716 | 0.80 | MDM2 (0.40) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL25363958 | 0.79 | SIRT1 (0.37) | CA1CA2SIRT5HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4556026-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4552654-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4480499-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | ERLIN1, WEE1, ERLIN2 | CA1 2573/4885CA2 4367/4885MAPT 1794/4885 |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | CA1 3250/4885CA2 4620/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.